The Asia Pacific Clot Busting Drugs Market should witness market growth of 8.9% CAGR during the forecast period (2023-2030).
Demand for clot-busting drugs is expected to rise as cardiovascular disorders, such as heart attacks and strokes, become more common. The rising incidence of strokes necessitates a prompt response, and clot-busting drugs can assist by dissolving blood clots in vessels, thereby reducing blood pressure. Strokes are raising mortality rates among people, increasing demand for clot-busting drugs. Additionally, it is anticipated that the market for clot-busting drugs will expand during the projected period due to the rising incidence of ischemic stroke.
The rise in the senior population, chronic illnesses, neurological disorders, etc., are another significant market driver throughout the projection period. The market is expanding due to various symptoms, including fatigue, dilated pupils, impaired vision, dizziness, losing balance while walking, paralysis, and stiff neck. Additionally, variables that will impact market growth in the near future include an unhealthy diet, a rise in alcohol use, a rise in smoking, and an upsurge in diabetics. The market will expand over the projected period due to technology advancements and manufacturer efforts to produce cutting-edge medical treatments and devices for stroke victims.
As per WHO, one of the world's populations that is aging at the fastest rate is China. As a result of rising life expectancy and falling birth rates, China's population of individuals over 60 is expected to increase to 28% by 2040. The goal is to make it possible for its citizens to age well, live longer and in better health, take advantage of opportunities for lifelong learning, and actively participate in and engage with their community. With rise in the aging population, the market is estimated to grow as the old aged population is more at a risk of getting such health conditions.
The China market dominated the Asia Pacific Clot Busting Drugs Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $3.9 billion by 2030. The Japan market is anticipated to grow at a CAGR of 8.2% during (2023-2030). Additionally, The India market would register a CAGR of 9.5% during (2023-2030).
Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. Based on Product, the market is segmented into Anticoagulants, Thrombolytic Drugs, Anti-Platelet Drugs and Others. Based on Route of Administration, the market is segmented into Injectable and Oral. Based on Indication, the market is segmented into Pulmonary Embolism, Atrial Fibrillation, Deep Vein Thrombosis and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Sanofi S.A., Dr. Reddy’s Laboratories Ltd., Bayer AG, Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Ltd., Bristol Myers Squibb Company, Eli Lilly And Company, Johnson & Johnson (Johnson & Johnson Services, Inc.), Pfizer, Inc., Merck & Co., Inc.
Demand for clot-busting drugs is expected to rise as cardiovascular disorders, such as heart attacks and strokes, become more common. The rising incidence of strokes necessitates a prompt response, and clot-busting drugs can assist by dissolving blood clots in vessels, thereby reducing blood pressure. Strokes are raising mortality rates among people, increasing demand for clot-busting drugs. Additionally, it is anticipated that the market for clot-busting drugs will expand during the projected period due to the rising incidence of ischemic stroke.
The rise in the senior population, chronic illnesses, neurological disorders, etc., are another significant market driver throughout the projection period. The market is expanding due to various symptoms, including fatigue, dilated pupils, impaired vision, dizziness, losing balance while walking, paralysis, and stiff neck. Additionally, variables that will impact market growth in the near future include an unhealthy diet, a rise in alcohol use, a rise in smoking, and an upsurge in diabetics. The market will expand over the projected period due to technology advancements and manufacturer efforts to produce cutting-edge medical treatments and devices for stroke victims.
As per WHO, one of the world's populations that is aging at the fastest rate is China. As a result of rising life expectancy and falling birth rates, China's population of individuals over 60 is expected to increase to 28% by 2040. The goal is to make it possible for its citizens to age well, live longer and in better health, take advantage of opportunities for lifelong learning, and actively participate in and engage with their community. With rise in the aging population, the market is estimated to grow as the old aged population is more at a risk of getting such health conditions.
The China market dominated the Asia Pacific Clot Busting Drugs Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $3.9 billion by 2030. The Japan market is anticipated to grow at a CAGR of 8.2% during (2023-2030). Additionally, The India market would register a CAGR of 9.5% during (2023-2030).
Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. Based on Product, the market is segmented into Anticoagulants, Thrombolytic Drugs, Anti-Platelet Drugs and Others. Based on Route of Administration, the market is segmented into Injectable and Oral. Based on Indication, the market is segmented into Pulmonary Embolism, Atrial Fibrillation, Deep Vein Thrombosis and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Sanofi S.A., Dr. Reddy’s Laboratories Ltd., Bayer AG, Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Ltd., Bristol Myers Squibb Company, Eli Lilly And Company, Johnson & Johnson (Johnson & Johnson Services, Inc.), Pfizer, Inc., Merck & Co., Inc.
Scope of the Study
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By Product
- Anticoagulants
- Thrombolytic Drugs
- Anti-Platelet Drugs
- Others
By Route of Administration
- Injectable
- Oral
By Indication
- Pulmonary Embolism
- Atrial Fibrillation
- Deep Vein Thrombosis
- Others
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Sanofi S.A.
- Dr. Reddy’s Laboratories Ltd.
- Bayer AG
- Boehringer Ingelheim International GmbH
- Sun Pharmaceutical Industries Ltd.
- Bristol Myers Squibb Company
- Eli Lilly And Company
- Johnson & Johnson (Johnson & Johnson Services, Inc.)
- Pfizer, Inc.
- Merck & Co., Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Asia Pacific Clot Busting Drugs Market by Distribution Channel
Chapter 5. Asia Pacific Clot Busting Drugs Market by Product
Chapter 6. Asia Pacific Clot Busting Drugs Market by Route of Administration
Chapter 7. Asia Pacific Clot Busting Drugs Market by Indication
Chapter 8. Asia Pacific Clot Busting Drugs Market by Country
Chapter 9. Company Profiles
Companies Mentioned
- Sanofi S.A.
- Dr. Reddy’s Laboratories Ltd.
- Bayer AG
- Boehringer Ingelheim International GmbH
- Sun Pharmaceutical Industries Ltd.
- Bristol Myers Squibb Company
- Eli Lilly And Company
- Johnson & Johnson (Johnson & Johnson Services, Inc.)
- Pfizer, Inc.
- Merck & Co., Inc.
Methodology
LOADING...
